Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study
Clinical and Molecular Hepatology · 2025
DOI: 10.3350/cmh.2024.0898 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Bingtian Dong und 59 weiteren Autor:innen. Beteiligte Einrichtung: Liver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School, Southeast Uni…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Esophageal and Gastric Varices, Machine Learning. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Jiangsu Province, Southeast University.
Abstract (Originalsprache)
Background/Aims: A large percentage of patients undergoing esophagogastroduodenoscopy (EGD) screening do not have esophageal varices (EV) or have only small EV. We evaluated a large, international, multicenter cohort to develop a novel score, termed FIB-4plus, by combining the fibrosis-4 (FIB-4) score, liver stiffness measurement (LSM), and spleen stiffness measurement (SSM) to identify high-risk EV (HRV) in compensated cirrhosis.
Methods
This international cohort study involved patients with compensated cirrhosis from 17 Chinese hospitals and one Croatian institution (NCT04546360). Two-dimensional shear wave elastography-derived LSM and SSM values, and components of the FIB-4 score (i.e., age, aspartate aminotransferase, alanine aminotransferase, and platelet count [PLT]) were combined using machine learning algorithms (logistic regression [LR] and extreme gradient boosting [XGBoost]) to develop the LR-FIB-4plus and XGBoost-FIB-4plus models, respectively. Shapley Additive exPlanations method was used to interpret the model predictions.
Results
We analyzed data from 502 patients with compensated cirrhosis who underwent EGD screening. The XGBoost-FIB-4plus score demonstrated superior predictive performance for HRV, with an area under the receiver operating characteristic curve (AUROC) of 0.927 (95% confidence interval [CI] 0.897–0.957) in the training cohort (n=268), and 0.919 (95% CI 0.843–0.995) and 0.902 (95% CI 0.820–0.984) in the first (n=118) and second (n=82) external validation cohorts, respectively. Additionally, the XGBoost-FIB-4plus score exhibited high AUROC values for predicting EV across all cohorts. The FIB-4plus score outperformed the individual parameters (LSM, SSM, PLT, and FIB-4).
Conclusions
The FIB-4plus score effectively predicted EV and HRV in patients with compensated cirrhosis, providing clinicians with a valuable tool for optimizing patient management and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of…
- Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of Ultrasound, Donggang Branch the First Hospital of Lanzhou University, Lanzhou, China.
- The First Clinical Medical College of Lanzhou University, Lanzhou, Lanzhou, China.
- Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, University of Zagreb School of Medicine and Faculty of Pharmacy and Biochemistry, Zagreb, Croatia.
Förderung
- National Natural Science Foundation of China
- Key Research and Development Program of Jiangsu Province
- Southeast University
- Zhongda Hospital
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
- Health Research Program of Anhui
Zitieren
APA
Dong, B., He, R., Ju, S., Chen, Y., Grgurevic, I., Ma, J., Guo, Y., Fan, H., Yan, Q., Liu, C., Xu, H., Madir, A., Podrug, K., Wang, J., Qian, L., Geng, Z., Liu, S., Ren, T., Zhang, G., …, & Dietrich, C. F. (2025). Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0898
Vancouver
Dong B, He R, Ju S, Chen Y, Grgurevic I, Ma J, et al. Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0898
BibTeX
@article{Dong2025,
author = {Dong, Bingtian and He, Ruiling and Ju, Shenghong and Chen, Yuping and Grgurevic, Ivica and Ma, Jianzhong and Guo, Ying and Fan, Huizhen and Yan, Qiang and Liu, Chuan and Xu, Huixiong and Madir, Anita and Podrug, Kristian and Wang, Jia and Qian, Linxue and Geng, Zhengzi and Liu, Shanghao and Ren, Tao and Zhang, Guo and Wang, Kun and Su, Meiqin and Chen, Fei and Ma, Sumei and Zhang, Liting and Tong, Zhaowei and Zhou, Yonghe and Li, Xin and He, Fanbin and Huan, Hui and Wang, Wenjuan and Liang, Yunxiao and Tang, Juan and Ai, Fang and Wang, Tingyu and Zheng, Liyun and Zhao, Zhongwei and Ji, Jiansong and Liu, Wei and Xu, Jiaojiao and Liu, Bo and Wang, Xuemei and Zhang, Yao and Yan, Qiong and Liu, Hui and Chen, Xiaomei and Zhang, Shuhua and Wang, Yihua and Liu, Yang and Yin, Li and Liu, Yanni and Huang, Yanqing and Bian, Li and An, Ping and Zhang, Xin and Zhang, Shaoting and Shao, Jinhua and Zhang, Xiangman and Rao, Wei and Zhang, Chaoxue and Dietrich, Christoph Frank},
title = {Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study},
journal = {Clinical and Molecular Hepatology},
year = {2025},
doi = {10.3350/cmh.2024.0898}
}
EUVIMED